Skip to content

Clinical Study of autologous blood injection for the treatment of recurrent temporomandibular joint dislocation

Clinical Study of autologous blood injection for the treatment of recurrent temporomandibular joint dislocation - Autologous blood injection for recurrent temporomandibular joint dislocation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000022197
Enrollment
20
Registered
2016-05-09
Start date
2016-05-09
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent temporomandibular joint (TMJ) dislocation

Interventions

1) The procedure is applied under local anesthesia. The skin overlying the TMJ is scrubbed with 10% povidone iodine and local anesthesia with 1% lidocaine including 1/80000 adrenaline is given to the
s anticubital fossa. 3) The syringe is connected to the previous inserted needle and blood is injected-3ml in the superior joint space and 1 ml in the pericapsular tissue. 4) After completion of the

Sponsors

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Department of Oral and Maxillofacial Surgery
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) The patient was diagnosed as having recurrent TMJ dislocation based on the clinical criteria of Nitzan. The patient has the episodes of condylar dislocation for several times. 2) The conservative methods including restriction of the mandibular motions with chin cap, bandage, maxillomandibular fixation, or mouth opening training based on the self-reduce TMJ dislocation were ineffective. 3) A written informed consent must be obtained by an investigator from the patient or the legally authorized representative before the procedure.

Exclusion criteria

Exclusion criteria: 1) Inflammatory diseases of temporomandibular joint, such as rheumatoid arthritis, tuberculous arthritis. 2) Evidence of tumor or tumor like lesion in the TMJ. 3) Temporomandibular disorders caused by metabolic diseases, including crystal deposition diseases such as gout, pseudogout, or crystal arthritis. 4) Intercurrent facial palsy. 5) Serious concomitant systemic disorder, including malignant hypertension, history of severe cardiovascular diseases or cerebrovascular disorders within 6 months, hemorrhagic gastric ulcers, uncontrolled diabetes, apparent bleeding tendency. 6) Under anticoagulant therapy. 7) Suspicion for active infection. 8) History of serious psychiatric illness or psychiatry illness under medical treatment. 9) Others diagnosed as inapplicable cases by an investigator.

Design outcomes

Primary

MeasureTime frame
At follow-up 6 months after the procedure, there is no episode of TMJ dislocation.

Secondary

MeasureTime frame
Improvement of QOL by decreasing the frequency of TMJ dislocation.

Countries

Japan

Contacts

Public ContactNORIE YOSHIOKA

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Department of Oral and Maxillofacial Surgery

noriy@md.okayama-u.ac.jp086-235-6702

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026